Brainsway Ltd (BWAY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Brainsway Ltd (BWAY) has a cash flow conversion efficiency ratio of 0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.17 Million) by net assets ($75.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Brainsway Ltd (BWAY) net asset quality to measure how much of total assets are equity-financed.
Brainsway Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Brainsway Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Brainsway Ltd (BWAY) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Brainsway Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brainsway Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
N/A |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
N/A |
|
CSB Bank Limited
NSE:CSBBANK
|
-0.248x |
|
Gladstone Commercial Corporation
NASDAQ:GOOD
|
0.109x |
|
SZZT Electronics Co Ltd
SHE:002197
|
0.019x |
|
Bright Minds Biosciences Inc
NASDAQ:DRUG
|
-0.031x |
|
Selamat Sempurna Tbk
JK:SMSM
|
0.072x |
|
China Fortune Land Development Co Ltd
SHG:600340
|
0.076x |
Annual Cash Flow Conversion Efficiency for Brainsway Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Brainsway Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Brainsway Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $73.22 Million | $18.16 Million | 0.248x | +50.10% |
| 2024-12-31 | $62.31 Million | $10.30 Million | 0.165x | +435.19% |
| 2023-12-31 | $41.58 Million | $1.28 Million | 0.031x | +114.36% |
| 2022-12-31 | $45.40 Million | $-9.76 Million | -0.215x | -1494.17% |
| 2021-12-31 | $57.33 Million | $884.00K | 0.015x | +121.08% |
| 2020-12-31 | $19.63 Million | $-1.44 Million | -0.073x | +75.55% |
| 2019-12-31 | $24.22 Million | $-7.24 Million | -0.299x | +44.89% |
| 2018-12-31 | $6.95 Million | $-3.77 Million | -0.543x | -99.13% |
| 2017-12-31 | $12.72 Million | $-3.47 Million | -0.273x | -16.72% |
| 2016-12-31 | $10.29 Million | $-2.40 Million | -0.233x | +33.85% |
| 2015-12-31 | $12.89 Million | $-4.55 Million | -0.353x | -44.97% |
| 2014-12-31 | $15.58 Million | $-3.79 Million | -0.244x | -50.97% |
| 2013-12-31 | $14.65 Million | $-2.36 Million | -0.161x | +77.22% |
| 2012-12-31 | $7.92 Million | $-5.60 Million | -0.708x | -- |
About Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, … Read more